{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010419","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.996113+00:00","generated_at":"2026-06-11T21:01:20.188024+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders","bullets":["Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.","Phase 2 trial of bremelanotide co-formulated with a PDE5i expected to start Q4 2023.","Published data show synergy between bremelanotide and PDE5i via distinct mechanisms.","Bremelanotide is the active agent in Vyleesi, approved for HSDD in women.","Palatin successfully co-formulated bremelanotide with a PDE5i for single injection."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010419","json":"https://secwatch.observer/filing/0001654954-23-010419.json","markdown":"https://secwatch.observer/filing/0001654954-23-010419.md","text":"https://secwatch.observer/filing/0001654954-23-010419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423010419/0001654954-23-010419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423010419/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T21:01:20.188024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}